ARWR ARROWHEAD PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 879407 · Fiscal year ends 09/30
Financial factors as of 2026-09-30 (2026Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-45.6%
TTM net income YoY-44,302.3%
TTM EPS YoY-51,000.0%
Revenue 3-yr CAGR23.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-156.9%
Net margin-160.6%
FCF margin-63.0%
EBITDA margin-151.4%
Returns
ROE-280.5%
ROA-46.4%
ROIC (approx.)-492.0%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets97.1%
Debt / equity0.00x
Current ratio4.14x
Interest coverage-7.55x
Cash quality & payout
Operating cash flow / net income0.38x
Accruals ratio-29.0%
Payout ratio—
Capex / revenue2.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q4*2026-09-30 | 2026Q32026-06-30 | 2026Q22026-03-31 | 2026Q12025-12-31 | 2025Q4*2025-09-30 | 2025Q32025-06-30 | 2025Q22025-03-31 | 2025Q12024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $37.79M | $75.25M | $73.74M | $264.03M | $256.47M | $27.77M | $542.71M | $2.50M |
| R&D expense | $190.47M | $198.22M | $173.25M | $177.20M | $174.69M | $162.37M | $133.10M | $137.00M |
| SG&A expense | $67.16M | $47.12M | $41.74M | $46.02M | $37.68M | $30.95M | $28.41M | $26.91M |
| Operating income | -$436.63M | -$170.09M | -$141.26M | $40.81M | $44.11M | -$165.55M | $381.20M | -$161.41M |
| Interest expense | $22.80M | $24.56M | $23.85M | $22.50M | $21.69M | $24.38M | $21.64M | $21.65M |
| Pretax income | -$435.71M | -$178.91M | -$137.56M | $28.27M | $36.12M | -$179.09M | $369.62M | -$175.12M |
| Income tax | -$6.83M | $11,000 | $7,000 | $29,000 | $20.00M | -$437,000 | $1.75M | $103,000 |
| Net income | -$428.00M | -$194.28M | -$132.73M | $30.81M | -$23.75M | -$175.24M | $370.44M | -$173.09M |
| EBITDA | -$430.03M | -$163.89M | -$135.36M | $46.81M | $50.11M | -$159.75M | $386.80M | -$156.61M |
| EPS (basic) | — | -1.36 | -0.93 | 0.22 | — | -1.26 | 2.78 | -1.39 |
| EPS (diluted) | — | -1.36 | -0.93 | 0.22 | — | -1.26 | 2.75 | -1.39 |
| Weighted avg. shares (diluted) | — | 143.38M | 142.42M | 140.71M | — | 139.04M | 134.48M | 124.85M |
| Balance sheet | ||||||||
| Cash & equivalents | $62.73M | $54.76M | $188.52M | $201.64M | $226.55M | $129.79M | $185.71M | $53.89M |
| Short-term investments | $1.13B | $1.55B | $1.60B | $714.97M | $692.82M | $770.58M | $911.70M | $499.05M |
| Receivables | $9.93M | $8.56M | $15.69M | $218.87M | $6.82M | $0 | $2.37M | $2.50M |
| Inventory | $9.07M | — | — | — | $0 | — | — | — |
| Current assets | $1.29B | $1.67B | $1.84B | $1.17B | $950.64M | $946.92M | $1.14B | $570.54M |
| PP&E, net | $371.31M | $373.30M | $374.82M | $378.58M | $382.51M | $381.05M | $384.80M | $387.07M |
| Intangibles | $5.16M | $5.59M | $6.01M | $6.44M | $6.86M | $7.29M | $7.71M | $8.14M |
| Total assets | $1.74B | $2.11B | $2.27B | $1.60B | $1.39B | $1.38B | $1.57B | $1.01B |
| Current liabilities | $311.34M | $283.35M | $295.22M | $347.43M | $195.49M | $194.53M | $220.54M | $93.76M |
| Total liabilities | $1.69B | $1.65B | $1.67B | $1.04B | $881.88M | $860.81M | $889.27M | $957.62M |
| Shareholders' equity | $50.31M | $465.53M | $613.98M | $568.42M | $466.05M | $522.31M | $683.32M | $52.59M |
| Shares outstanding | 141.29M | 141.13M | 140.57M | 137.39M | 135.70M | 138.14M | 138.06M | 125.57M |
| Cash flow statement | ||||||||
| Operating cash flow | -$192.40M | -$177.47M | $84.44M | $13.48M | $20.49M | -$154.72M | $460.05M | -$146.27M |
| Capital expenditure | $3.43M | $3.85M | $2.56M | $2.15M | $7.49M | $2.36M | $5.30M | $7.52M |
| Free cash flow | -$195.83M | -$181.32M | $81.88M | $11.33M | $13.00M | -$157.08M | $454.76M | -$153.79M |
| Investing cash flow | $203.86M | $43.68M | -$894.28M | -$23.74M | $72.62M | $141.39M | -$420.21M | $76.91M |
| Financing cash flow | -$3.70M | -$449,000 | $795.72M | -$14.75M | $3.67M | -$42.68M | $92.38M | $20.63M |
| Depreciation & amortization | $6.60M | $6.20M | $5.90M | $6.00M | $6.00M | $5.80M | $5.60M | $4.80M |
| Stock-based compensation | $17.23M | $14.97M | $16.57M | $19.37M | $19.09M | $11.99M | $15.08M | $15.21M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.